CEL-SCI CORPORATION (CVM) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -50.08×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | -50.08× | Operating income ÷ reported interest expense. $-22.29M ÷ $445.00K ≈ -50.08× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 14.80M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 1.79M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -22.29M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 445.00K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.80M | (m) | $1.79M | $-22.29M | $445.00K | (m) | (m) | -50.08× | Reported |
| 2026-03-31 | $14.89M | (m) | $1.41M | $-22.22M | $506.00K | (m) | (m) | -43.91× | Reported |
| 2025-12-31 | $15.13M | (m) | $1.64M | $-23.29M | $567.00K | (m) | (m) | -41.07× | Reported |
| 2025-09-30 | $15.89M | (m) | $1.91M | $-24.81M | $649.00K | (m) | (m) | -38.23× | Reported |
| 2025-06-30 | $16.66M | (m) | $2.20M | $-24.90M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $17.62M | (m) | $2.85M | $-26.08M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $18.24M | (m) | $3.60M | $-26.76M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $18.16M | (m) | $4.27M | $-26.35M | $745.67K | (m) | (m) | -35.34× | Reported |
| 2024-06-30 | $18.95M | (m) | $4.85M | $-27.70M | (m) | (m) | (m) | (m) | (m) |
| 2024-04-19 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $19.98M | (m) | $5.67M | $-29.21M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $21.43M | (m) | $5.98M | $-30.31M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $22.47M | (m) | $6.29M | $-31.48M | $675.42K | (m) | (m) | -46.60× | Reported |
| 2023-06-30 | $23.67M | (m) | $7.26M | $-32.96M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $24.22M | (m) | $8.17M | $-33.49M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $24.66M | (m) | $9.82M | $-34.87M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $25.36M | (m) | $11.39M | $-36.06M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $24.18M | (m) | $12.70M | $-35.59M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $25.08M | (m) | $13.76M | $-37.33M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $23.78M | (m) | $13.65M | $-36.31M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $23.11M | (m) | $13.69M | $-36.19M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $22.98M | (m) | $13.51M | $-36.17M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $19.77M | (m) | $13.11M | $-32.67M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $19.00M | (m) | $11.61M | $-30.86M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $17.84M | (m) | $10.11M | $-28.99M | $1.20M | (m) | (m) | -24.15× | Reported |
| 2020-06-30 | $15.90M | (m) | $8.49M | $-26.02M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $14.95M | (m) | $6.90M | $-24.32M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $13.38M | (m) | $5.65M | $-21.96M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $12.66M | (m) | $4.43M | $-20.20M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $9.64M | (m) | $3.18M | $-18.08M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $9.77M | (m) | $2.12M | $-16.96M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $10.21M | (m) | $1.87M | $-16.88M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $9.40M | (m) | $2.74M | $-16.77M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $10.01M | (m) | $2.57M | $-16.92M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $10.77M | (m) | $2.43M | $-17.61M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $14.38M | (m) | $2.52M | $-21.31M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $15.61M | (m) | $1.38M | $-21.34M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $19.45M | (m) | $1.85M | $-26.15M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $20.63M | (m) | $1.95M | $-27.29M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $18.21M | (m) | $2.00M | $-25.18M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $19.35M | (m) | $2.11M | $-25.55M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $19.88M | (m) | $1.80M | $-26.78M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $20.77M | (m) | $2.00M | $-28.60M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $21.24M | (m) | $2.47M | $-30.08M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $20.95M | (m) | $5.11M | $-34.30M | $129.99K | (m) | (m) | -263.85× | Reported |
| 2015-06-30 | $19.96M | (m) | $7.04M | $-34.47M | $166.57K | (m) | (m) | -206.93× | Reported |
| 2015-03-31 | $18.72M | (m) | $6.88M | $-33.17M | $166.70K | (m) | (m) | -198.97× | Reported |
| 2014-12-31 | $17.84M | (m) | $6.51M | $-31.64M | $162.75K | (m) | (m) | -194.38× | Reported |
| 2014-09-30 | $17.00M | $264.03K | $3.96M | $-27.57M | $163.77K | 6438.64% | 1499.30% | -168.37× | Reported |
| 2014-06-30 | $16.10M | (m) | (m) | $-24.13M | $164.70K | (m) | (m) | -146.53× | Reported |
| 2014-03-31 | $15.42M | (m) | (m) | $-22.75M | $165.68K | (m) | (m) | -137.29× | Reported |
| 2013-12-31 | $13.78M | (m) | (m) | $-20.76M | $171.70K | (m) | (m) | -120.90× | Reported |
| 2013-09-30 | $12.68M | $159.58K | (m) | $-19.87M | $170.42K | 7946.37% | (m) | -116.58× | Reported |
| 2013-06-30 | $12.06M | (m) | (m) | $-19.12M | $169.21K | (m) | (m) | -113.00× | Reported |
| 2013-03-31 | $10.37M | (m) | (m) | $-17.82M | $167.91K | (m) | (m) | -106.13× | Reported |
| 2012-12-31 | $10.84M | (m) | (m) | $-17.84M | $180.15K | (m) | (m) | -99.05× | Reported |
| 2012-09-30 | $10.37M | $254.61K | (m) | $-17.24M | $262.21K | 4072.38% | (m) | -65.76× | Reported |
| 2012-06-30 | $10.03M | (m) | (m) | $-16.65M | $-251.21K | (m) | (m) | (m) | Reported |
| 2012-03-31 | $10.49M | (m) | (m) | $-17.28M | $-226.37K | (m) | (m) | (m) | Reported |
| 2011-12-31 | $10.94M | (m) | (m) | $-18.11M | $-240.92K | (m) | (m) | (m) | Reported |
| 2011-09-30 | $11.75M | (m) | (m) | $-17.99M | $-322.98K | (m) | (m) | (m) | Reported |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | $11.91M | (m) | (m) | $-18.56M | $-162.33K | (m) | (m) | (m) | Reported |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | $6.01M | (m) | $685.86K | $-12.02M | $-397.92K | (m) | (m) | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |